P. Southwell David's Insider Trades & SAST Disclosures
P. Southwell David's most recent trade in PTC Therapeutics Inc was a trade of 8,800 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern P. Southwell David.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 8,800 | 8,800 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 4,000 | 16,850 (0%) | 0% | 0 | Common Stock | |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 23,944 | 23,944 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 08 May 2024 | 1,650 | 12,850 (0%) | 0% | 0 | Common Stock | |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 May 2024 | 113,124 | 1,660 (0%) | 0% | 0 | Common Stock | |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 May 2024 | 59,716 | 113,124 (0%) | 0% | 0 | Common Stock | |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2024 | 70,000 | 29,624 | - | - | Stock Option (Right to Buy) | |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.34 per share. | 12 Apr 2024 | 70,000 | 165,160 (0%) | 0% | 4.3 | 303,940 | Common Stock |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 24.22 per share. | 12 Apr 2024 | 59,716 | 105,444 (0%) | 0% | 24.2 | 1,446,560 | Common Stock |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.34 per share. | 12 Apr 2024 | 29,624 | 124,784 (0%) | 0% | 4.3 | 128,627 | Common Stock |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2024 | 29,624 | 0 | - | - | Stock Option (Right to Buy) | |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 25.16 per share. | 12 Apr 2024 | 10,284 | 95,160 (0%) | 0% | 25.2 | 258,704 | Common Stock |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 24.05 per share. | 12 Apr 2024 | 10,000 | 114,784 (0%) | 0% | 24.1 | 240,520 | Common Stock |
|
PTC Therapeutics Inc
|
P. David Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
P. Southwell David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 14,500 (0%) | 0% | 0 | Common Stock | |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 25,850 | 25,850 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 11,429 | 0 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.01 per share. | 17 Apr 2023 | 11,429 | 21,929 (0%) | 0% | 18.0 | 205,836 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 50.69 per share. | 17 Apr 2023 | 6,241 | 15,688 (0%) | 0% | 50.7 | 316,348 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 51.43 per share. | 17 Apr 2023 | 5,188 | 10,500 (0%) | 0% | 51.4 | 266,840 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 50.05 per share. | 31 Mar 2023 | 2,571 | 10,500 (0%) | 0% | 50.0 | 128,672 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,571 | 11,429 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.01 per share. | 31 Mar 2023 | 2,571 | 13,071 (0%) | 0% | 18.0 | 46,304 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.05 per share. | 27 Mar 2023 | 10,000 | 20,500 (0%) | 0% | 27.1 | 270,500 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2023 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 45.41 per share. | 27 Mar 2023 | 5,301 | 10,600 (0%) | 0% | 45.4 | 240,735 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 44.71 per share. | 27 Mar 2023 | 4,599 | 15,901 (0%) | 0% | 44.7 | 205,618 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 46.03 per share. | 27 Mar 2023 | 100 | 10,500 (0%) | 0% | 46.0 | 4,603 | Common Stock |
|
Tscan Therapeutics Inc
|
David P. Southwell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 4,000 | 10,500 (0%) | 0% | 0 | Common Stock | |
|
Tscan Therapeutics Inc
|
David P. Southwell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 47,745 | 47,745 | - | - | Stock Option (Right to Buy) | |
|
Tscan Therapeutics Inc
|
David P. Southwell | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 18 May 2022 | 15,000 | 161,569 | - | 3.6 | 54,339 | Voting Common Stock |
|
Tscan Therapeutics Inc
|
David P. Southwell | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.55 per share. | 18 May 2022 | 10,000 | 171,569 | - | 3.5 | 35,482 | Voting Common Stock |
|
Tscan Therapeutics Inc
|
David P. Southwell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 12,000 | 12,000 | - | - | Stock Option (Right To Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 3,200 | 6,500 (0%) | 0% | 0 | Common Stock | |
|
Tscan Therapeutics Inc
|
David P. Southwell | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 48,670 | 21,161 | - | - | Stock Option (Right to Buy) | |
|
Tscan Therapeutics Inc
|
David P. Southwell | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.97 per share. | 23 Dec 2021 | 48,670 | 146,569 | - | 2.0 | 95,880 | Voting Common Stock |
|
Tscan Therapeutics Inc
|
David P. Southwell | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 8.73 per share. | 08 Sep 2021 | 11,000 | 97,899 | - | 8.7 | 96,066 | Voting Common Stock |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 12,236 | 12,236 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2021 | 1,650 | 3,300 (0%) | 0% | 0 | Common Stock | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.85 per share. | 16 Oct 2020 | 15,000 | 16,650 (0%) | 0% | 10.9 | 162,750 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 51.50 per share. | 16 Oct 2020 | 14,300 | 2,350 (0%) | 0% | 51.5 | 736,493 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.23 per share. | 16 Oct 2020 | 12,000 | 13,650 (0%) | 0% | 11.2 | 134,760 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 51.52 per share. | 16 Oct 2020 | 11,500 | 2,150 (0%) | 0% | 51.5 | 592,434 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 52.18 per share. | 16 Oct 2020 | 700 | 1,650 (0%) | 0% | 52.2 | 36,528 | Common Stock |
|
PTC Therapeutics Inc
|
David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 52.18 per share. | 16 Oct 2020 | 500 | 1,650 (0%) | 0% | 52.2 | 26,089 | Common Stock |
|
Rocket Pharmaceuticals Inc
|
David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges